Interventions for minimal change disease in adults with nephrotic syndrome

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Palmer, Suetonia C ^a   Nand, K ^b   Strippoli, G F ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HEPARINOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC TEST; FOLLOW UP; HUMAN; INCIDENCE; NEPHROTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW;

EID: 44949157929     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001537.pub4     Document Type: Review

References (93)

1. Coggins 1985 {published data only} *Coggins CH. Adultminimal change nephropathy: experience of the collaborative study of glomerular disease. Transactions of the American Clinical & Climatological Asoociation 1985;97:18-26. [MEDLINE: 3915841].
2. Imbasciati 1985 {published data only} *Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C, Grassi C, et al.Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. British Medical Journal Clinical Research Ed 1985;291(6505):1305-8. [MEDLINE: 3933645].
3. Yeung 1983 {published data only} *Yeung CK, Wong KL, Ng WL. Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome. Australian & New Zealand Journal of Medicine 1983;13(4):349-51. [MEDLINE: 6580858].
4. Abaigar 1993 *Abaigar LP, Torres G, Vazquez A, De Toro R, Santos J, Carrasco ML, et al.Influence of protein contents of the diet and angiotensin converting inhibitors in the adult nephrotic syndrome. Randomized and crossed, prospective study. Nefrologia 1993;13(Suppl 5):87-93.
5. Arora 2002 *Arora A, Ahlawat RS, Arora S, Mandel AK. Randomised controlled study of enalapril in steroid resistant nephrotic syndrome. Indian Journal of Nephrology 2002;12(3):http://www. ijnephrol.com/july_sep02/articleq13.html.
6. Bagga 1997 *Bagga A, Ekka BK, Srivastava RN. Single versus divided dose prednisolone therapy for relapses of nephrotic syndrome (NS) [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A113.
7. Bagga 1999 Bagga A, Hari P, Srivastava RN. Long (lp) versus standard (sp) initial prednisolone treatment for nephrotic syndrome (ns) [abstract]. Nephrology, Urology, Transplantation Society of SAARC, Sri Lanka. 1999:158.
8. *Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatric Nephrology 1999;13(9):824-7. [MEDLINE: 10603129].
9. Bargman 1999 *Bargman JM. Management of minimal lesion glomerulonephritis: Evidence-based recommendations. Kidney International - Supplement 1999;55:S3-16. [MEDLINE: 10369190].
10. Beige 2003 *Beige J, Moosmayer I, Liefeldt L, Neumayer HH, Zidek W, Peters H. Effective and safe treatment of primary nephrotic syndrome with tacrolimus (FK506) [abstract]. Nephrology Dialysis Transplantation. 2003; Vol. 18, issue Suppl 4:65.
11. Black 1970 *Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. British Medical Journal 1970;3(5720):421-6. [MEDLINE: 4916790].
12. Broyer 1995 *Broyer M, Terzi F, Gagnadoux MF, Guest G, Niaudet P. A randomised double blind study of deflazacort (d) versus prednisone (p) in the treatment of idiopathic nephrotic syndrome (ins) [abstract]. Journal of the American Society of Nephrology. 1995; Vol. 6, issue 3:414.
13. Choi 2002 *Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, et al.Mycophenolate mofetil treatment for primary glomerular diseases. Kidney International 2002;61(3):1098-114. [MEDLINE: 11849465].
14. Cole 1994 *Cole B. Cyclosporine for nephrotic syndrome - isn't it time for a collaborative trial?. Journal of the American Society of Nephrology 1994;5(4):1047-8. [MEDLINE: 7849243].
15. Deighan 2001 *Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. Journal of the American Society of Nephrology 2001;12(2):341-8. [MEDLINE: 11158224].
16. Dilek 1999 *Dilek K, Yavus M, Usta M, Ersoy A, Ilcol YO, Gullulu M, et al.The comparison of antiproteinuric effects of angiotensin converting enzyme inhibitor enalapril and angiotensin ii receptor antagonist losartan in nephrotic syndrome cases [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A88.
17. Don 1989 *Don BR, Wada L, Kaysen GA, Schambelan M. Effect of dietary protein restriction and angiotensin converting enzyme inhibition on protein metabolism in the nephrotic syndrome. Kidney International - Supplement 1989;27:S163-7. [MEDLINE: 2561515].
18. El-Reshaid 1995 *El-Reshaid K, Amer E, Madda JP, Kapoor M. Long-term cyclosporin A treatment in adults with refractory nephrotic syndrome. Renal Failure 1995;17(6):695-703. [MEDLINE: 8771242].
19. Gentile 1993 *Gentile MG, Fellin G, Cofano F, Delle FA, Manna G, Ciceri R, et al.Treatment of proteinuric patients with a vegetarian soy diet and fish oil. Clinical Nephrology 1993;40(6):315-20. [MEDLINE: 8299238].
20. Groggel 1989 *Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney International 1989;36(2):266-71. [MEDLINE: 2779095].
21. Gulati 1973 Gulati PD, Bazaz MG, Vaishnava H. A double-blind trial of "alternate-day" steroid therapy in adult nephrotics - a preliminary report. Journal of the Association of Physicians of India 1970;18(12):963-73. [MEDLINE: 5509033].
22. *Gulati PD, Malik GB, Vaishnava H. Alternate-day steroid therapy in adult nephrotics. Journal of Medicine 1973;4(5):266-75. [MEDLINE: 4589645].
23. Ishikawa 1982 *Ishikawa H, Honjo A, Hayashi M, Hamaguchi T, Morita T, Shindo T, et al.Effects of dipyridamole on proteinuria in chronic glomerulonephritis and the nephrotic syndrome. Arzneimittel-Forschung 1982;32(3):301-9. [MEDLINE: 7200790].
24. Ishikawa H, Honjo A, Hayashi M, Hamaguchi T, Morita T, Tesutani T, et al.The therapeutical effect of dipyridamole on chronic glomerulonephritis and nephrotic syndrome in large dose administration - the study in a double blind group comparison method. Nippon Jinzo Gakkai Shi. Japanese Journal of Nephrology 1979;21(2):135-55. [MEDLINE: 381736].
25. Koike 2002 *Koike M, Honda K, Tsukada M, Itabashi M, Suzuki K, Uchida K, et al.Low-dose cyclosporin therapy combined with prednisolone for relapsing minimal change nephrotic syndrome in adults. Nippon Jinzo Gakkai Shi. Japanese Journal of Nephrology 2002;44(5):447-52. [MEDLINE: 12216477].
26. Kumar 2004 Kumar NS, Mishra RN, Singh AK, Prakash J. Effect of Ace inhibitor and calcium channel blocker on proteinuria in subjects with steroid resistant idiopathic nephrotic syndrome [abstract]. Indian Journal of Nephrology 2001;11(3):110-1.
27. *Kumar NS, Singh AK, Mishra SN, Prakash J. Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome. Journal of the Association of Physicians of India 2004;52:454-8. [MEDLINE: 15645954].
28. Lee 1995 *Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea. Clinical Nephrology 1995;43(6):375-81. [MEDLINE: 7554521].
29. Leisti 1978 *Leisti S, Koskimies O, Perheentupa J, Vilska J, Hallman N. Idiopathic nephrotic syndrome: prevention of early relapse. British Medical Journal 1978; Vol. 1, issue 6117:892. [MEDLINE: 346147].
30. Mansy 1989 *Mansy H, Goodship TH, Tapson JS, Hartley GH, Keavey P, Wilkinson R. Effect of a high protein diet in patients with the nephrotic syndrome. Clinical Science 1989;77(4):445-51. [MEDLINE: 2805603].
31. Martins 1994 Martins PM, Nogueira AC, Reimao PJ, Correia AM, Vicente O, Rodrigues MC, et al.Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome. Clinical Nephrology 1994;41(5):277-83. [MEDLINE: 8050207].
32. Matl 1997 Matl I, Matousovic K, Herout V, Konecny K, Kovac A, Rychlik I, et al.A controlled clinical trial of Consupren versus cyclophosphamide in chronic glomerulonephritis. Casopis Lekaru Ceskych 1997;136(4):120-123. [MEDLINE: 9221182].
33. *Matl I, Matousovic K, Herout V, Konency K, Kovac A, Rychlik I, et al.A controlled clinical study of Consupren versus Cyclophosphamide in chronic glomerulonephritis. I. Efficacy of therapy. Casopis Lekaru Ceskych 1997;136(4):120-3.
34. Matsubara 2002 *Matsubara M, Nogae S, Ito S. Novel trial for the treatment of steroid dependency in minimal change disease: Combined therapy of camostat mesilate and glycyrrhizin. Nephron 2002;90(3):357-60. [MEDLINE: 11867962].
35. Matsumoto 2004 *Matsumoto H, Nakao T, Okada T, Nagaoka Y, Takeguchi F, Tomaru R, et al.Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Internal Medicine 2004;43(8):668-73. [MEDLINE: 15468963].
36. Matzkies 1999 *Matzkies FH, Bahner U, Teschner M, Hohage H, Heidland A, Schaefer RM. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. American Journal of Nephrology 1999;19(4):492-4. [MEDLINE: 10460940].
37. Meyrier 1988 *Meyrier A, Condamin MC, Simon P. Treatment with cyclosporine of adult idiopathic nephrotic syndrome resistant to corticosteroid and other immunosuppressants. Transplantation Proceedings 1988;20 (3 Suppl 4):259-61.
38. Meyrier 1991 *Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clinical Nephrology 1991;35(1):S37- 42. [MEDLINE: 1860266].
39. Meyrier 1994 *Meyrier A, Noel L-H, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney International 1994;45(5):1446-56. [MEDLINE: 8072258].
40. Meyrier 1996 *Meyrier A. Use of cyclosporine A in the treatment of refractory nephrotic syndrome in adults. Renal Failure 1996;18(5):775-84. [MEDLINE: 8903092].
41. Mocan 1997 *Mocan H, Mocan MZ. The effect of high dose methylprednisolone therapy in patients with minimal change nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A74.
42. Naigui 1997 *Naigui X, Jian X, Jing H. A clinical study on low dose cyclosporin a with diltiazem in the treatment of primary nephrotic syndrome [abstract]. Nephrology 1997;3(Suppl 1):S125.
43. Ni 2003 *Ni ZH, Qian JQ, Lin AW, Mu S, Zhu ML, Fang W. A controlled, prospective study of efficacy of leflunomide in patients with nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):524A.
44. Niaudet 1994 *Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. Journal of the American Society of Nephrology 1994;5(4):1049-56. [MEDLINE: 7849244].
45. Olbricht 1999 *Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney International - Supplement 1999;71:S113-6. [MEDLINE: 10412752].
46. Pecoraro 2003 *Pecoraro C, Caropreso MR, Passaro G, Fereto AV, Malgieri G. Therapy of first episode of steroid responsive nephrotic syndrome: a randomised controlled trial [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):63.
47. Piccoli 1993 *Piccoli A, Gastaldon F, Pillon L, Mussap M, Faggian D, Plebani M, et al.Bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome. A pilot study. Current Therapeutic Research - Clinical and Experimental 1993;54(5):588-97.
48. Pirisi 1998 *Pirisi M, Faedda R, Satta A, Bartoli E. Immunosuppressive treatment for idiopathic syndrome with corticosteroids and cyclophosphamide. Factors associated with a favorable outcome. Clinical Drug Investigation 1998;16(3):211-8.
49. Ponticelli 1993 Ponticelli C. A multicenter controlled prospective trial with cyclosporine vs cyclophosphamide in frequent relapsers and steroid dependent patients with idiopathic nephrotic syndrome. Journal of Nephrology 1989;2(2):147-51.
50. Ponticelli C. Ciclosporin in the treatment of idiopathic nephrotic syndrome [abstract]. 10th Asian Colloquium in Nephrology; 1994 Dec 2-6; Karachi (Pakistan). 1994:116.
51. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al.Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrology Dialysis Transplantation 1993;8(12):1326-32. [MEDLINE: 8159300].
52. Ponticelli 1993A *Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al.A randomized trial of cyclosporine in steroid resistant idiopathic nephrotic syndrome. Kidney International 1993;43(6):1377-84. [MEDLINE: 8315953].
53. Rabelink 1988 *Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988;2(8624):1335-8. [MEDLINE: 2904053].
54. Reichert 1999 *Reichert LJ, Koene RA, Wetzels JF. Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Nephrology Dialysis Transplantation 1999;14(1):91-7. [MEDLINE: 10052484].
55. Sharpstone 1969 *Sharpstone P, Ogg CS, Cameron JS. Nephrotic syndrome due to primary renal disease in adults: II.A controlled trial of prednisone and azathioprine. British Medical Journal 1969;2(5656): 535-9. [MEDLINE: 4890207].
56. Shibasaki 2004 *Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al.A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clinical & Experimental Nephrology 2004;8(2):117-26. [MEDLINE: 15235928].
57. Spitalewitz 1993 *Spitalewitz S, Porush JG, Cattran D, Wright N. Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. American Journal of Kidney Diseases 1993;22(1):143-50. [MEDLINE: 8322777].
58. Sural 2001 *Sural S, Pahari DK, Mitra K, Bhattacharya S, Mondal S, Taraphder A. Efficacy of levamisole compared to cyclophosphamide and steroid in frequently in frequently relapsing (FR) minimal change nephrotic syndrome (MCNS) [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):126A.
59. Tejani 1988 *Tejani A, Gonzalez R, Rajpoot D, Sharma R, Pomrantz A. A randomized trial of cyclosporine with low-dose prednisone compared with high-dose prednisone in nephrotic syndrome. Transplantation Proceedings 1988;20(3 Suppl 4):262-4. [MEDLINE: 3381280].
60. Thomas 1993 *Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, et al.Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International 1993;44(5):1124-9. [MEDLINE: 8264145].
61. Toto 2000 *Toto RD, Grundy SM, Vega GL. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. American Journal of Nephrology 2000;20(1):12-7. [MEDLINE: 10644862].
62. Uldall 1972 *Uldall PR, Feest TG, Morley AR, Tomlinson BE, Kerr DN. Cyclophosphamide therapy in adults with minimal change nephrotic syndrome. Lancet 1972;1(7763):1250-3. [MEDLINE: 4113514].
63. Wyszynska 1988 *Wyszynska T, Ksiasek J, Uszycka-Karcz M, Kobierska-Szczepanska A, Morawska Z, Zoch-Zwierz W. Evaluation of prednisolone pulse therapy in steroid-resistant nephrotic syndrome. A multicenter collaborative study. Contributions to Nephrology 1988;67:229-32. [MEDLINE: 3061742].
64. Ye 1993 *Ye R, Zhang D. Contrasting efficacy of two different treatment programs in adult frequently relapsing nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts).
65. Yoshikawa 1995 *Yoshikawa N, Tanaka R, Kitano Y, Nakamura H, Ito H. Long-term cyclosporin in steroid-dependent nephrotic syndrome. Contributions to Nephrology 1995;114:19-27. [MEDLINE: 7587196].
66. Al Khader 1979 Al-Khader AA, Lien JW, Aber GM. Cyclophosphamide alone in the treatment of adult patients withminimal change glomerulonephritis. Clinical Nephrology 1979;11(1):26-30. [MEDLINE: 428152].
67. Arneil 1961 Arneil GC. 164 children with nephrosis. Lancet 1961;II:1103-10.
68. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al.Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9. [MEDLINE: 8773637].
69. Briggs 1998 Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. American Journal of Kidney Diseases 1998;31(2):213-7. [MEDLINE: 9469489].
70. Day 2002 Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolatemofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrology Dialysis Transplantation 2002;17(11):2011-3. [MEDLINE: 12401863].
71. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286- 91. [MEDLINE: 7718048].
72. Durkan 2005 Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2005, Issue 2.Art. No.: CD002290. DOI:10.1002/14651858.CD002290.pub2.
73. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315(7109):629-34. [MEDLINE: 9310563].
74. EUVAS 2006 The European Vasculitis Study Group. http://www.vasculitis.org (accessed November 2007).
75. Grimbert 2003 Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrology Dialysis Transplantation 2003;18(2):245-8. [MEDLINE: 12543875].
76. Haas 1995 Haas M, Spargo BH, Coventry S. Increasing incidence of focal segmental glomerulosclerosis among adult nephropathies. American Journal of Kidney Diseases 1995;26(5):740-50. [MEDLINE: 7485126].
77. Haas 1997 Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. American Journal of Kidney Diseases 1997;30(5):621-31. [MEDLINE: 9370176].
78. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ 2003;327(7414):557- 60. [MEDLINE: 12958120].
79. Hodson 2006 Hodson EM, Habashy D, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD003594. DOI:10.1002/14651858.CD003594.pub3.
80. Hodson 2007 Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2007, Issue 4.Art. No.: CD001533. DOI:10.1002/14651858.CD001533. pub4.
81. Johnson 2003 Johnson RJ, Feehally J (editors). Comprehensive clinical nephrology. 2nd Edition. Edinburgh: Mosby, Elsevier Limited, 2003.
82. Korbet 1996 Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. American Journal of Kidney Diseases 1996;27(5):647-51. [MEDLINE: 8629623].
83. Lefebvre 1996 Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia). 1996.
84. Mak 1996 Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrology Dialysis Transplantation 1996;11(11):2192-201. [MEDLINE: 8941578].
85. Master List 2007 United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed May 2007).
86. Mogyorosi 2002 Mogyorosi A, Lippman HR, Feldman GM. Successful treatment of steroid-resistant minimal change disease with mycophenolate mofetil. American Journal of Nephrology 2002;22(5-6):569-72. [MEDLINE: 12381961].
87. Nakayama 2002 Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fuijimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. American Journal of Kidney Diseases 2002;39(3):503-12. [MEDLINE: 11877569].
88. Nolasco 1986 Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney International 1986;29(6):1215-23. [MEDLINE: 3747335].
89. Patel 2005 Patel P, Pal S, Ashley C, Sweny P, Burns A. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report. Nephrology Dialysis Transplantation 2005;20(5):985-7. [MEDLINE: 15741203].
90. Schweda 1997 Schweda F, Liebl R, Riegger GA, Kramer BK. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrology Dialysis Transplantation 1997;12(11):2433-5. [MEDLINE: 9394341].
91. Tse 2003 Tse KC, Lam MF, Yip PS, Li FK, Choy BY, Lai KN, et al.Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrology Dialysis Transplantation 2003;18(7):1316-20. [MEDLINE: 12808168].
92. Westhoff 2006 Westhoff TH, Schmidt S, Zidek W, Beige J, van der Giet M. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clinical Nephrology 2006;65(6):393-400. [MEDLINE: 16792133].
93. Woo 2001 Woo KT, Chew ST, Vathsala A, Chiang GS. Case reports of low dose cyclosporine. A therapy in adult minimal change nephrotic syndrome. Annals of the Academy of Medicine, Singapore 2001;30(4):430-5. [MEDLINE: 11503553].